Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.61 |
| ▸ | MMP9 | P14780 | 9/20 | 0.61 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383079 | 1.00 | MMP2 (0.61) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| Hydrochloric Acid SCHEMBL382133 | 0.98 | MMP2 (0.59) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| Hydrochloric Acid SCHEMBL7336920 | 0.98 | MMP2 (0.59) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL7370003 | 0.92 | MMP2 (0.72) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL8091793 | 0.85 | MMP2 (0.63) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL7375346 | 0.85 | SLC1A3 (0.60) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL14608753 | 0.85 | MMP2 (0.53) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL3861153 | 0.85 | MMP2 (0.53) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL4041728 | 0.85 | TDP1 (0.63) | MMP2MMP9ADAMTS4MMP13MMP8 | |
| SCHEMBL7337519 | 0.85 | TDP1 (0.63) | MMP2MMP9ADAMTS4MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010107832-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2010-09-23 | — | — | WO | disclosed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| CN-1173957-C | Substituted piperazones and their therapeutic use | L���������鹫˾ | 2004-11-03 | — | — | CN | disclosed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-0760658-B1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0901373-B1 | Alpha v Beta 3 ANTAGONISTS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-0667773-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0673247-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0673247-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0667773-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995017397-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5416099-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1995-05-16 | — | — | US | disclosed |
| WO-1995004531-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| WO-1994008577-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | MMP2 977/4885MMP9 1038/4885ADAMTS4 2323/4885 |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | MMP2 951/4885MMP9 1110/4885ADAMTS4 1637/4885 |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | LHCGR, GNRHR, FSHR | MMP2 3768/4885MMP9 4370/4885ADAMTS4 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.